Related Experiment Video

Updated: Feb 7, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.3K

Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib

Suheil Albert Atallah-Yunes1, Myat Han Soe1

  • 1Department of Medicine, Baystate-University of Massachusetts Medical School, Springfield, MA, USA.

Case Reports in Hematology
|July 31, 2018
PubMed

Insights

This study reports the first case of ixazomib-induced thrombotic microangiopathy (DTMA) caused by cumulative toxicity, not immune response. It highlights precipitating factors, diagnosis, and management of this rare drug-induced condition.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Drug-induced thrombotic microangiopathies (DTMAs) are a recognized complication of cancer therapies.
  • Proteasome inhibitors (PIs) are frequently implicated in DTMAs, acting via immune or toxic mechanisms.

More Related Videos

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.6K
Measuring RAN Peptide Toxicity in C. elegans10:49

Measuring RAN Peptide Toxicity in C. elegans

Published on: April 30, 2020

7.1K

Related Concept Videos

Cumulative Frequency Distribution01:04

Cumulative Frequency Distribution

A cumulative frequency distribution is another type of frequency distribution. Instead of reporting how many data values fall in some classes, it reports how many data values are contained in either that class or any class to its left. Technically, it means the sum of frequencies of the class and all the classes below it in a frequency distribution. A cumulative frequency is calculated by adding the frequency of each class lower than the corresponding class interval or category. In general, a...
8.5K
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
2.0K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
451
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
162
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
273
Induced-fit Model01:13

Induced-fit Model

Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
89.4K